Sujet(s)
Sténose aortique , Valve aortique , Maladie de la valve aortique bicuspide , Prise de décision clinique , Valvulopathies , Prothèse valvulaire cardiaque , Sélection de patients , Remplacement valvulaire aortique par cathéter , Humains , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/instrumentation , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/physiopathologie , Valve aortique/malformations , Résultat thérapeutique , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/physiopathologie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Valvulopathies/chirurgie , Valvulopathies/imagerie diagnostique , Valvulopathies/physiopathologie , Facteurs de risque , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Appréciation des risques , Conception de prothèseRÉSUMÉ
BACKGROUND: Outcomes from transcatheter aortic valve replacement (TAVR) in low-surgical risk patients with bicuspid aortic stenosis beyond 2 years are limited. OBJECTIVES: This study aimed to evaluate 3-year clinical and echocardiographic outcomes from the Evolut Low Risk Bicuspid Study. METHODS: The Evolut Low Risk Bicuspid Study is a prospective, multicenter, single-arm study conducted in 25 U.S. CENTERS: Patients with severe aortic stenosis at low surgical risk with bicuspid aortic valve anatomy (all subtypes) underwent TAVR with a self-expanding, supra-annular Evolut R or PRO (Medtronic) bioprosthesis. An independent clinical events committee adjudicated all deaths and endpoint-related adverse events, and a central echocardiographic core laboratory assessed hemodynamic endpoints. RESULTS: An attempted implant was performed in 150 patients from December 2018 to October 2019. The mean age was 70.3 ± 5.5 years, 48% (72/150) of the patients were women, and the mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 1.3% (Q1-Q3: 0.9%-1.7%). Sievers type 1 was the dominant bicuspid morphology (90.7%, 136/150). The Kaplan-Meier rates of all-cause mortality or disabling stroke were 1.3% (95% CI: 0.3%-5.3%) at 1 year, 3.4% (95% CI: 1.4%-8.1%) at 2 years, and 4.1% (95% CI: 1.6%-10.7%) at 3 years. The incidence of new permanent pacemaker implantation was 19.4% (95% CI: 12.4%-29.6%) at 3 years. There were no instances of moderate or severe paravalvular aortic regurgitation at 2 and 3 years after TAVR. CONCLUSIONS: The 3-year results from the Evolut Low Risk Bicuspid Study demonstrate low rates of all-cause mortality or disabling stroke and favorable hemodynamic performance.
Sujet(s)
Sténose aortique , Valve aortique , Maladie de la valve aortique bicuspide , Bioprothèse , Prothèse valvulaire cardiaque , Hémodynamique , Conception de prothèse , Remplacement valvulaire aortique par cathéter , Humains , Femelle , Mâle , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Sténose aortique/mortalité , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/mortalité , Remplacement valvulaire aortique par cathéter/instrumentation , Sujet âgé , Facteurs de risque , Études prospectives , Facteurs temps , Résultat thérapeutique , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/physiopathologie , Valve aortique/malformations , Appréciation des risques , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/physiopathologie , États-Unis/épidémiologie , Indice de gravité de la maladie , Complications postopératoires/mortalité , Récupération fonctionnelle , Sujet âgé de 80 ans ou plus , Adulte d'âge moyen , Valvulopathies/physiopathologie , Valvulopathies/imagerie diagnostique , Valvulopathies/chirurgie , Valvulopathies/mortalitéSujet(s)
Sténose aortique , Valve aortique , Maladie de la valve aortique bicuspide , Remplacement valvulaire aortique par cathéter , Humains , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/instrumentation , Résultat thérapeutique , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/physiopathologie , Valve aortique/malformations , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Maladie de la valve aortique bicuspide/physiopathologie , Maladie de la valve aortique bicuspide/complications , Facteurs de risque , Prothèse valvulaire cardiaque , Valvulopathies/chirurgie , Valvulopathies/imagerie diagnostique , Valvulopathies/physiopathologie , Valvulopathies/complications , Prise de décision clinique , Récupération fonctionnelle , Appréciation des risquesSujet(s)
Calcinose , Valve atrioventriculaire gauche , Humains , Calcinose/imagerie diagnostique , Calcinose/physiopathologie , Valve atrioventriculaire gauche/imagerie diagnostique , Valve atrioventriculaire gauche/physiopathologie , Valve atrioventriculaire gauche/chirurgie , Implantation de valve prothétique cardiaque/instrumentation , Implantation de valve prothétique cardiaque/effets indésirables , Valvulopathies/imagerie diagnostique , Valvulopathies/physiopathologie , Valvulopathies/chirurgie , Valvulopathies/complications , Résultat thérapeutique , Lésions traumatiques du coeur/imagerie diagnostique , Lésions traumatiques du coeur/étiologieRÉSUMÉ
OBJECTIVE: To investigate the accuracy and consistency of MDCT and TEE in the preoperative assessment of aortic root surgery. METHODS: From January 2021 to September 2022, 118 patients who underwent aortic root surgery were included in this study. All patients underwent high-quality preoperative MDCT and TEE examinations, and the examination results were independently measured and assessed by two senior radiologists or ultrasound specialists. Bland-Altman analysis and Pearson correlation testing were employed to assess the correlation and consistency between MDCT and TEE. These analyses were then compared with actual intraoperative measurement data. RESULTS: Among all the patients, 73 (61.86%) had tricuspid aortic valve (TAV), and 45 (38.14%) had bicuspid aortic valve (BAV). A comparison between the TEE and MDCT measurements showed that for the annulus diameter, the area-derived diameter had the best correlation and agreement. For the sinus of Valsalva diameter, the circumference-derived diameter was optimal. However, for the STJ diameter, the minimum cross-sectional diameter showed the best agreement with TEE. In contrast, measurements of geometric height showed a weaker correlation and agreement. CONCLUSION: Contrast-enhanced MDCT can be a valuable tool for perioperative evaluation in aortic root surgery, with good correlation, consistency, and feasibility when compared to TEE. The choice of MDCT measurement methodology, specifically area-derived and circumference-derived diameter, proved to be more accurate than other methods. Further research is required to enhance the understanding of aortic valve repair and associated imaging techniques.
Sujet(s)
Valve aortique , Maladie de la valve aortique bicuspide , Échocardiographie transoesophagienne , Tomodensitométrie multidétecteurs , Valeur prédictive des tests , Humains , Valve aortique/imagerie diagnostique , Valve aortique/chirurgie , Valve aortique/malformations , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , Reproductibilité des résultats , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Adulte , Études rétrospectives , Valvulopathies/imagerie diagnostique , Valvulopathies/chirurgie , Soins préopératoiresRÉSUMÉ
Accurate evaluation of the mitral valve (MV) apparatus is essential for understanding the mechanisms of MV disease across various clinical scenarios. The mitral annulus (MA) is a complex and crucial structure that supports MV function; however, conventional imaging techniques have limitations in fully capturing the entirety of the MA. Moreover, recognizing annular changes might aid in identifying patients who may benefit from advanced cardiac imaging and interventions. Multimodality cardiovascular imaging plays a major role in the diagnosis, prognosis, and management of MV disease. Transthoracic echocardiography is the first-line modality for evaluation of the MA, but it has limitations. Cardiac MRI (CMR) has emerged as a robust imaging modality for assessing annular changes, with distinct advantages over other imaging techniques, including accurate flow and volumetric quantification and assessment of variations in the measurements and shape of the MA during the cardiac cycle. Mitral annular disjunction (MAD) is defined as atrial displacement of the hinge point of the MV annulus away from the ventricular myocardium, a condition that is now more frequently diagnosed and studied owing to recent technical advances in cardiac imaging. However, several unresolved issues regarding MAD, such as the functional significance of pathologic disjunction and how this disjunction advances in the clinical course, require further investigation. The authors review the role of CMR in the assessment of MA disease, with a focus on MAD and its functional implications in MV prolapse and mitral regurgitation. ©RSNA, 2024 Supplemental material is available for this article. See the invited commentary by Stojanovska and Fujikura in this issue.
Sujet(s)
Imagerie par résonance magnétique , Valve atrioventriculaire gauche , Humains , Valve atrioventriculaire gauche/imagerie diagnostique , Imagerie par résonance magnétique/méthodes , Insuffisance mitrale/imagerie diagnostique , Valvulopathies/imagerie diagnostiqueSujet(s)
Valve atrioventriculaire gauche , Humains , Valve atrioventriculaire gauche/imagerie diagnostique , Valve atrioventriculaire gauche/physiopathologie , Insuffisance mitrale/imagerie diagnostique , Insuffisance mitrale/physiopathologie , Diagnostic différentiel , Mâle , Femelle , Valvulopathies/imagerie diagnostiqueRÉSUMÉ
The presence of bright resonance of more than 1 mm or more cusps of the aortic valve, mitral valve or mitral annulus is termed as cardiac valve calcification. If an intense echo producing structure located at the junction of the atrioventricular groove and posterior mitral valve leaflet on Echocardiography that is Mitral annular calcification (MAC). This study was conducted to observe the association of MAC with clinical and echocardiographic findings of ischemic heart disease (IHD) and the role of trans-thoracic echocardiography to detect MAC which is a marker IHD. In this prospective, observational, case-control study, total of 100 IHD patients, 50 patients with MAC were assigned as case group and 50 patients without MAC were control group after fulfilling inclusion criteria. All the detailed history, clinical examination and relevant investigation reports of each patient were recorded in pre designed data collection sheet. MAC was detected with transthorasic echocardiography. Analysis was done to observe the association and correlation of MAC with clinical findings of IHD. Mean age of the case control was 55.16±10.73 years and control was 49.80±8.84 years. MAC was noted highest about 56.0% in between age 45 to 60 years. Eighty two percent (82.0%) of cases and 84.0% of controls were male, 18.0% of cases and 16.0% of controls were female. BMI among the MAC group 2.0% were underweight, 72.0% normal, 24.0% over weight and 2.0% were obese and among non MAC controls group 10.0% were underweight, 68.0% normal, 20.0% over weight and 2.0% were obese. Clinically among cases 14(28.0%) had Stable angina, 8(16.0%) had UA, 3(6.0%) had Non STEMI, 2(4.0%) had AMI, 2(4.0%) had Recent myocardial infarction and 21(42.0%) had OMI. Diabetes mellitus was significantly higher in the case groups (p=0.006). Significant p-value was noted in hyper-triyglyceridemia and low HDL in case group than control. Echocardiographic studies showed 52.0% of cases and 32.0% of controls had regional wall motion abnormality (RWMA). Transthorasic echocardiographically detected MAC is an independent predictor of Ischemic heart disease. The low cost, portable and radiation free nature of the ultrasound approach make MAC an attractive parameter in the ongoing search for IHD.
Sujet(s)
Calcinose , Échocardiographie , Valve atrioventriculaire gauche , Ischémie myocardique , Centres de soins tertiaires , Humains , Mâle , Femelle , Adulte d'âge moyen , Ischémie myocardique/imagerie diagnostique , Calcinose/imagerie diagnostique , Études cas-témoins , Échocardiographie/méthodes , Valve atrioventriculaire gauche/imagerie diagnostique , Valve atrioventriculaire gauche/anatomopathologie , Études prospectives , Valvulopathies/imagerie diagnostique , Valvulopathies/complications , Sujet âgé , AdulteRÉSUMÉ
AIMS: With an ageing population, the presence of asymptomatic valvular heart disease (VHD) in the community remains unknown. The aim of this study is to determine the prevalence and associated factors of asymptomatic VHD in individuals ≥60 years old and to evaluate the feasibility of echocardiographic screening for VHD in this population. METHODS AND RESULTS: This was a prospective cohort study conducted between 2007 and 2016 in the UK. Asymptomatic patients with no prior indication for echocardiography were invited to participate and evaluated with a health questionnaire, clinical examination, and transthoracic echocardiography. A total of 10,000 individuals were invited through their general practices. A total of 5429 volunteered to participate, of whom 4237 were eligible for inclusion. VHD was diagnosed in more than a quarter of patients (28.2%). The most common types of VHD were regurgitation of the tricuspid (13.8%), mitral (12.8%), and aortic (8.3%) valves (trivial regurgitation was not included). The rate of prevalence of clinically significant VHD was 2.4% (2.2% moderate and 0.2% severe), with mitral and aortic regurgitation being the most common. The only parameter associated with significant VHD was age (odds ratio 1.07 per 1 year increment, 95% confidence interval 1.05-1.09, P < 0.001). The number needed to scan to diagnose one clinically significant case of VHD is 42 for individuals ≥60 and 15 for those ≥75 years old. CONCLUSION: Asymptomatic VHD is present in a significant proportion of otherwise healthy individuals without known VHD over 60 years old. Age is strongly associated with an increased incidence of significant VHD.
Sujet(s)
Maladies asymptomatiques , Échocardiographie , Valvulopathies , Humains , Femelle , Mâle , Sujet âgé , Études prospectives , Prévalence , Valvulopathies/imagerie diagnostique , Valvulopathies/épidémiologie , Adulte d'âge moyen , Maladies asymptomatiques/épidémiologie , Royaume-Uni/épidémiologie , Études de cohortes , Sujet âgé de 80 ans ou plus , Appréciation des risques , Facteurs âgesRÉSUMÉ
BACKGROUND: We conducted this study to assess the compliance with secondary rheumatic prophylaxis among preoperative patients with rheumatic mitral valve disease undergoing valvular heart surgery at a tertiary care cardiac hospital in a developing country. METHODS: This is a descriptive cross-sectional study conducted at a tertiary care cardiac hospital in Karachi, Pakistan. The inclusion criteria encompassed patients of any sex, aged between 18 and 80 years, who had been diagnosed with rheumatic mitral valve disease through transthoracic echocardiography and had undergone valvular heart surgery. The level of compliance with secondary rheumatic prophylaxis and barriers toward noncompliance was assessed during routine preoperative interview session. This preventive measure plays a crucial role in reducing the progression of the disease and improving patient outcomes. RESULTS: Out of the 239 patients included in the study, 125 (52.3%) were females, with a mean age of 38.8 ± 11.8 years. The majority of patients (88.7%) came from rural areas. Among the patients, 79 (33.1%) received rheumatic prophylaxis, while 160 (66.9%) did not adhere to it regularly. The common barriers for receiving rheumatic prophylaxis were non availability (41.0%) and nonaffordability (40.6%). Additionally, 28.0% of patients had lacked awareness of the importance of rheumatic prophylaxis, and 2.5% expressed fear of injection site pain and subsequent symptoms. CONCLUSIONS: A concerning level of noncompliance with secondary rheumatic prophylaxis was observed. The barriers identified in patients who did not receive rheumatic prophylaxis were primarily related to affordability, availability, lack of awareness, and fear of injection site pain and subsequent symptoms.
Sujet(s)
Connaissances, attitudes et pratiques en santé , Valve atrioventriculaire gauche , Rhumatisme cardiaque , Prévention secondaire , Humains , Femelle , Mâle , Rhumatisme cardiaque/chirurgie , Rhumatisme cardiaque/imagerie diagnostique , Études transversales , Adulte , Adulte d'âge moyen , Pakistan , Valve atrioventriculaire gauche/chirurgie , Valve atrioventriculaire gauche/imagerie diagnostique , Jeune adulte , Procédures de chirurgie cardiaque/effets indésirables , Adolescent , Observance par le patient , Sujet âgé , Facteurs de risque , Valvulopathies/chirurgie , Valvulopathies/imagerie diagnostique , Valvulopathies/complications , Conscience immédiate , Résultat thérapeutique , Adhésion aux directives , Sujet âgé de 80 ans ou plus , Pays en voie de développement , Centres de soins tertiaires , Soins préopératoires , Éducation du patient comme sujetRÉSUMÉ
BACKGROUND: Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis is technically challenging and is burdened by an increased risk of paravalvular regurgitation (PVR). OBJECTIVES: The aim of this study was to identify the incidence, predictors, and clinical outcomes of PVR after TAVR in Sievers type 1 BAV stenosis. METHODS: Consecutive patients with Sievers type 1 BAV stenosis undergoing TAVR with current-generation transcatheter heart valves (THVs) in 24 international centers were enrolled. PVR was graded as none/trace, mild, moderate, and severe according to echocardiographic criteria. The endpoint of major adverse events (MAEs), defined as a composite of all-cause death, stroke, or hospitalization for heart failure, was assessed at the last available follow-up. RESULTS: A total of 946 patients were enrolled. PVR occurred in 423 patients (44.7%)-mild, moderate, and severe in 387 (40.9%), 32 (3.4%), and 4 (0.4%) patients, respectively. Independent predictors of moderate or severe PVR were a larger virtual raphe ring perimeter (adjusted OR: 1.07; 95% CI: 1.02-1.13), severe annular or left ventricular outflow tract calcification (adjusted OR: 5.21; 95% CI: 1.45-18.77), a self-expanding valve (adjusted OR: 9.01; 95% CI: 2.09-38.86), and intentional supra-annular THV positioning (adjusted OR: 3.31; 95% CI: 1.04-10.54). At a median follow-up of 1.3 years (Q1-Q3: 0.5-2.4 years), moderate or severe PVR was associated with an increased risk of MAEs (adjusted HR: 2.52; 95% CI: 1.24-5.09). CONCLUSIONS: After TAVR with current-generation THVs in Sievers type 1 BAV stenosis, moderate or severe PVR occurred in about 4% of cases and was associated with an increased risk of MAEs during follow-up.
Sujet(s)
Insuffisance aortique , Sténose aortique , Valve aortique , Maladie de la valve aortique bicuspide , Prothèse valvulaire cardiaque , Indice de gravité de la maladie , Remplacement valvulaire aortique par cathéter , Humains , Mâle , Femelle , Facteurs de risque , Sujet âgé , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/instrumentation , Remplacement valvulaire aortique par cathéter/mortalité , Insuffisance aortique/physiopathologie , Insuffisance aortique/imagerie diagnostique , Insuffisance aortique/étiologie , Insuffisance aortique/chirurgie , Sténose aortique/chirurgie , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Sténose aortique/mortalité , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/physiopathologie , Valve aortique/malformations , Résultat thérapeutique , Sujet âgé de 80 ans ou plus , Incidence , Facteurs temps , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Valvulopathies/imagerie diagnostique , Valvulopathies/chirurgie , Valvulopathies/physiopathologie , Europe , Appréciation des risques , Conception de prothèse , Odds ratio , Accident vasculaire cérébral/étiologie , Accident vasculaire cérébral/diagnostic , Défaillance cardiaque/physiopathologie , Défaillance cardiaque/étiologie , Défaillance cardiaque/diagnostic , Études rétrospectivesRÉSUMÉ
Patients with bicuspid aortic valve (BAV) commonly have associated aortic stenosis and aortopathy. The geometry of the aortic arch and BAV is not well defined quantitatively, which makes clinical classifications subjective or reliant on limited 2D measurements. The goal of this study was to characterize the 3D geometry of the aortic arch and BAV using objective and quantitative techniques. Pre-TAVR computed tomography angiogram (CTA) in patients with BAV and aortic stenosis (AS) were analyzed (n = 59) by assessing valve commissural angle, presence of a fused region, percent of fusion, and calcium volume. The ascending aorta and aortic arch were reconstructed from patient-specific imaging segmentation to generate a centerline and calculate maximum curvature and maximum area change for the ascending aorta and the descending aorta. Aortic valve commissural angle signified a bimodal distribution suggesting tricuspid-like (≤ 150°, 52.5% of patients) and bicuspid-like (> 150°, 47.5%) morphologies. Tricuspid like was further classified by partial (10.2%) or full (42.4%) fusion, and bicuspid like was further classified into valves with fused region (27.1%) or no fused region (20.3%). Qualitatively, the aortic arch was found to have complex patient-specific variations in its 3D shape with some showing extreme diameter changes and kinks. Quantitatively, subgroups were established using maximum curvature threshold of 0.04 and maximum area change of 30% independently for the ascending and descending aorta. These findings provide insight into the geometric structure of the aortic valve and aortic arch in patients presenting with BAV and AS where 3D characterization allows for quantitative classification of these complex anatomic structures.
Sujet(s)
Aorte thoracique , Valve aortique , Maladie de la valve aortique bicuspide , Imagerie tridimensionnelle , Humains , Maladie de la valve aortique bicuspide/imagerie diagnostique , Valve aortique/malformations , Valve aortique/imagerie diagnostique , Valve aortique/anatomopathologie , Aorte thoracique/imagerie diagnostique , Mâle , Femelle , Sujet âgé , Valvulopathies/imagerie diagnostique , Adulte d'âge moyen , Sténose aortique/imagerie diagnostique , Sténose aortique/physiopathologie , Sujet âgé de 80 ans ou plus , Angiographie par tomodensitométrieRÉSUMÉ
Frailty is a common clinical syndrome that portends poor peri-procedural outcomes and increased mortality following transcatheter valve interventions. We reviewed frailty assessment tools in transcatheter intervention cohorts to recommend a pathway for preprocedural frailty assessment in patients referred for transcatheter valve procedures, and evaluated current evidence for frailty interventions and their efficacy in transcatheter intervention. We recommend the use of a frailty screening instrument to identify patients as frail, with subsequent referral for comprehensive geriatric assessment in these patients, to assist in selecting appropriate patients and then optimizing them for transcatheter valve interventions. Interventions to reduce preprocedural frailty are not well defined, however, data from limited cohort studies support exercise-based interventions to increase functional capacity and reduce frailty in parallel with preprocedural medical optimization.
Sujet(s)
Personne âgée fragile , Fragilité , Évaluation gériatrique , Humains , Fragilité/diagnostic , Fragilité/physiopathologie , Résultat thérapeutique , Facteurs de risque , Sujet âgé , Appréciation des risques , Sujet âgé de 80 ans ou plus , Facteurs âges , Cathétérisme cardiaque/effets indésirables , État fonctionnel , Femelle , Mâle , Sélection de patients , Implantation de valve prothétique cardiaque/effets indésirables , Implantation de valve prothétique cardiaque/instrumentation , Valeur prédictive des tests , Remplacement valvulaire aortique par cathéter/effets indésirables , Remplacement valvulaire aortique par cathéter/mortalité , Prise de décision clinique , Valvulopathies/physiopathologie , Valvulopathies/chirurgie , Valvulopathies/mortalité , Valvulopathies/imagerie diagnostique , Valvulopathies/thérapie , État de santéRÉSUMÉ
Transthoracic echocardiography (TTE) is the most widely available and utilised imaging modality for the screening, diagnosis, and serial monitoring of all abnormalities related to cardiac structure or function. The primary objectives of this document are to provide (1) a guiding framework for treating clinicians of the acceptable indications for the initial and serial TTE assessments of the commonly encountered cardiovascular conditions in adults, and (2) the minimum required standard for TTE examinations and reporting for imaging service providers. The main areas covered within this Position Statement pertain to the TTE assessment of the left and right ventricles, valvular heart diseases, pericardial diseases, aortic diseases, infective endocarditis, cardiac masses, pulmonary hypertension, and cardiovascular diseases associated with cancer treatments or cardio-oncology. Facilitating the optimal use and performance of high quality TTEs will prevent the over or under-utilisation of this resource and unnecessary downstream testing due to suboptimal or incomplete studies.
Sujet(s)
Échocardiographie , Valvulopathies , Adulte , Humains , Cardiologie/méthodes , Cardiologie/normes , Échocardiographie/méthodes , Échocardiographie/normes , Valvulopathies/diagnostic , Valvulopathies/imagerie diagnostique , Sociétés médicales , Guides de bonnes pratiques cliniques comme sujetSujet(s)
Valve aortique , Maladie de la valve aortique bicuspide , Valvulopathies , Humains , Valve aortique/malformations , Valve aortique/chirurgie , Valve aortique/imagerie diagnostique , Valve aortique/physiopathologie , Maladie de la valve aortique bicuspide/chirurgie , Maladie de la valve aortique bicuspide/complications , Maladie de la valve aortique bicuspide/physiopathologie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Maladie de la valve aortique bicuspide/diagnostic , Valvulopathies/complications , Valvulopathies/imagerie diagnostique , Valvulopathies/chirurgie , Valvulopathies/physiopathologie , Tachycardie ventriculaire/diagnostic , Tachycardie ventriculaire/physiopathologie , Tachycardie ventriculaire/étiologie , Facteurs de risque , Potentiels d'actionRÉSUMÉ
BACKGROUND: Valvular heart disease (VHD) is becoming increasingly important to manage the risk of future complications. Electrocardiographic (ECG) changes may be related to multiple VHDs, and (AI)-enabled ECG has been able to detect some VHDs. We aimed to develop five deep learning models (DLMs) to identify aortic stenosis, aortic regurgitation, pulmonary regurgitation, tricuspid regurgitation, and mitral regurgitation. METHODS: Between 2010 and 2021, 77,047 patients with echocardiography and 12-lead ECG performed within 7 days were identified from an academic medical center to provide DLM development (122,728 ECGs), and internal validation (7,637 ECGs). Additional 11,800 patients from a community hospital were identified to external validation. The ECGs were classified as with or without moderate-to-severe VHDs according to transthoracic echocardiography (TTE) records, and we also collected the other echocardiographic data and follow-up TTE records to identify new-onset valvular heart diseases. RESULTS: AI-ECG adjusted for age and sex achieved areas under the curves (AUCs) of >0.84, >0.80, >0.77, >0.83, and >0.81 for detecting aortic stenosis, aortic regurgitation, pulmonary regurgitation, tricuspid regurgitation, and mitral regurgitation, respectively. Since predictions of each DLM shared similar components of ECG rhythms, the positive findings of each DLM were highly correlated with other valvular heart diseases. Of note, a total of 37.5-51.7% of false-positive predictions had at least one significant echocardiographic finding, which may lead to a significantly higher risk of future moderate-to-severe VHDs in patients with initially minimal-to-mild VHDs. CONCLUSION: AI-ECG may be used as a large-scale screening tool for detecting VHDs and a basis to undergo an echocardiography.
Sujet(s)
Intelligence artificielle , Électrocardiographie , Valvulopathies , Humains , Électrocardiographie/méthodes , Femelle , Mâle , Valvulopathies/diagnostic , Valvulopathies/imagerie diagnostique , Valvulopathies/physiopathologie , Sujet âgé , Adulte d'âge moyen , Apprentissage profond , Échocardiographie , Sujet âgé de 80 ans ou plusRÉSUMÉ
BACKGROUND: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification. METHODS: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46±13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were ≥18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter ≤50 mm. Computed tomography and echocardiography studies were performed at baseline and after 3 years of treatment. RESULTS: During follow-up, 28 patients (12.7%) discontinued medical treatment (15 on atorvastatin and 13 taking placebo). Thus, 192 patients completed the 36 months of treatment. Low-density lipoprotein cholesterol levels decreased significantly in the atorvastatin group (median [interquartile range], -30 mg/dL [-51.65 to -1.75 mg/dL] versus 6 mg/dL [-4, 22.5 mg/dL]; P<0.001). The maximum ascending aorta diameter increased with no differences between groups: 0.65 mm (95% CI, 0.45-0.85) in the atorvastatin group and 0.74 mm (95% CI, 0.45-1.04) in the placebo group (P=0.613). Similarly, no significant differences were found for the progression of the aortic valve calcium score (P=0.167) or valvular dysfunction. CONCLUSIONS: Among patients with bicuspid aortic valve without severe valvular dysfunction, atorvastatin treatment was not effective in reducing the progression of ascending aorta dilation and aortic valve calcification during 3 years of treatment despite a significant reduction in low-density lipoprotein cholesterol levels. REGISTRATION: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001808-57. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02679261.
Sujet(s)
Valve aortique , Atorvastatine , Maladie de la valve aortique bicuspide , Calcinose , Évolution de la maladie , Valvulopathies , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Humains , Atorvastatine/usage thérapeutique , Femelle , Mâle , Adulte d'âge moyen , Valve aortique/imagerie diagnostique , Valve aortique/anatomopathologie , Valve aortique/malformations , Valve aortique/effets des médicaments et des substances chimiques , Calcinose/traitement médicamenteux , Calcinose/imagerie diagnostique , Calcinose/anatomopathologie , Maladie de la valve aortique bicuspide/imagerie diagnostique , Maladie de la valve aortique bicuspide/traitement médicamenteux , Valvulopathies/traitement médicamenteux , Valvulopathies/imagerie diagnostique , Valvulopathies/anatomopathologie , Adulte , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Dilatation pathologique/traitement médicamenteux , Études de suivi , Méthode en double aveugle , Résultat thérapeutique , Aorte/imagerie diagnostique , Aorte/anatomopathologie , Aorte/effets des médicaments et des substances chimiques , Maladie de la valve aortique/traitement médicamenteux , Sténose aortiqueRÉSUMÉ
Cardiac Computed Tomography (CCT) has become a reliable imaging modality in cardiology providing robust information on the morphology and structure of the heart with high temporal and isotropic spatial resolution. For the past decade, there has been a paradigm shift in the management of valvular heart disease since previously unfavorable candidates for surgery are now provided with less-invasive interventions. Transcatheter heart valve interventions provide a real alternative to medical and surgical management and are often the only treatment option for valvular heart disease patients. Successful transcatheter valve interventions rely on comprehensive multimodality imaging assessment. CCT is the mainstay imaging technique for preprocedural planning of these interventions. CCT is critical in guiding patient selection, choice of procedural access, device selection, procedural guidance, as well as allowing postprocedural follow-up of complications. This article aims to review the current evidence of the role of CCT in the preprocedural planning of patients undergoing transcatheter valvular interventions.